Ivor Elrifi CEO of Tiziana Life Sciences commented, “We are thrilled to be able to progress our pipeline with this prestigious NIH grant, which underscores the potential of our anti-CD3 therapy ...
The development of better markers to detect early autoimmune β-cell destruction might allow optimal timing of anti-CD3 therapy in the future. The dosing in the failed Phase II trials was ...
discusses the potential role and limitations of anti-CD3 therapy in preventing T1D and preserving residual β-cell function. Severe eosinophilic asthma (SEA) is a respiratory condition ...
Ivor Elrifi CEO of Tiziana Life Sciences commented, “We are thrilled to be able to progress our pipeline with this prestigious NIH grant, which underscores the potential of our anti-CD3 therapy to ...
As the induction of Tregs is not dependent on the CD28-B7 pathway, [45] combination therapy of anti-CD3 antibody therapy and abatacept or other costimulatory blockade molecules might be complementary.
This significant grant will fund a key research study over the next several years, advancing preclinical and ultimately, clinical studies of intranasal anti-CD3 as a potential treatment for this ...
Ivor Elrifi CEO of Tiziana Life Sciences commented, “We are thrilled to be able to progress our pipeline with this prestigious NIH grant, which underscores the potential of our anti-CD3 therapy to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback